Evaluation of fatty acid amides in the carrageenan-induced paw edema model

Neuropharmacology

Volumn 54, Issue 1, 2008, Pages 181-188

  Wise, Laura E ^a   Cannavacciulo, Roberta ^a   Cravatt, Benjamin F ^b   Martin, Billy F ^a   Lichtman, Aron H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Edema; Endogenous cannabinoid; Fatty acid amide hydrolase (FAAH); Inflammation; N Arachidonoyl ethanolamine (anandamide); N Palmitoyl ethanolamine (PEA); THC

Indexed keywords

ANANDAMIDE; CARRAGEENAN; DEXAMETHASONE; DICLOFENAC; DRONABINOL; FATTY ACID AMIDASE; N OLEOYLETHANOLAMINE; OLEAMIDE; PALMIDROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERANCE; GENE DELETION; GENOTYPE; MALE; MOUSE; NONHUMAN; PAW EDEMA; PHENOTYPE; PRIORITY JOURNAL;

AMIDOHYDROLASES; ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; CARRAGEENAN; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EDEMA; ETHANOLAMINES; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLEIC ACIDS; POLYUNSATURATED ALKAMIDES; TETRAHYDROCANNABINOL;

EID: 37349085256     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.06.003     Document Type: Article

References (60)

1. Amann R., and Schuligoi R. Inhibition of carrageenan-induced edema by indomethacin or sodium salicylate does not prevent the increase of nerve growth factor in the rat hind paw. Neurosci. Lett. 278 (2000) 173-176
2. Basile A.S., Hanus L., and Mendelson W.B. Characterization of the hypnotic properties of oleamide. Neuroreport 10 (1999) 947-951
3. Berdyshev E., Boichot E., Corbel M., Germain N., and Lagente V. Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci. 63 (1998) PL125-PL129
4. Buritova J., Honore P., Chapman V., and Besson J.M. Enhanced effects of co-administered dexamethasone and diclofenac on inflammatory pain processing and associated spinal c-Fos expression in the rat. Pain 64 (1996) 559-568
5. Clayton N., Marshall F.H., Bountra C., and O'Shaughnessy C.T. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96 (2002) 253-260
6. Clement A.B., Hawkins E.G., Lichtman A.H., and Cravatt B.F. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. 23 (2003) 3916-3923
7. Coburn A.F., Graham C.E., and Haninger J. The effect of egg yolk in diets on anaphylactic arthritis (passive Arthus phenomenon) in the guinea pig. J. Exp. Med. 100 (1954) 425-435
8. Compton D.R., Aceto M.D., Lowe J., and Martin B.R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277 (1996) 586-594
9. Conti S., Costa B., Colleoni M., Parolaro D., and Giagnoni G. Anti-inflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br. J. Pharmacol. 135 (2002) 181-187
10. Costa B., Giagnoni G., and Colleoni M. Precipitated and spontaneous withdrawal in rats tolerant to anandamide. Psychopharmacology (Berlin) 149 (2000) 121-128
11. Costa B., Conti S., Giagnoni G., and Colleoni M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br. J. Pharmacol. 137 (2002) 413-420
12. Cravatt B.F., and Lichtman A.H. The endogenous cannabinoid system and its role in nociceptive behavior. J. Neurobiol. 61 (2004) 149-160
13. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., and Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996) 83-87
14. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., and Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 9371-9376
15. Cravatt B.F., Saghatelian A., Hawkins E.G., Clement A.B., Bracey M.H., and Lichtman A.H. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 10821-10826
16. De Petrocellis L., Davis J.B., and Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 506 (2001) 253-256
17. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
18. Di Marzo V., Bisogno T., De Petrocellis L., Brandi I., Jefferson R.G., Winckler R.L., Davis J.B., Dasse O., Mahadevan A., Razdan R.K., and Martin B.R. Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. Biochem. Biophys. Res. Commun. 281 (2001) 444-451
19. Di Marzo V., Melck D., Orlando P., Bisogno T., Zagoory O., Bifulco M., Vogel Z., and De Petrocellis L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 358 (2001) 249-255
20. Elmes S.J., Winyard L.A., Medhurst S.J., Clayton N.M., Wilson A.W., Kendall D.A., and Chapman V. Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 118 (2005) 327-335
21. Farquhar-Smith W.P., and Rice A.S. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology 94 (2001) 507-513 (discussion 506A)
22. Farquhar-Smith W.P., and Rice A.S. A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology 99 (2003) 1391-1401
23. Fedorova I., Hashimoto A., Fecik R.A., Hedrick M.P., Hanus L.O., Boger D.L., Rice K.C., and Basile A.S. Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J. Pharmacol. Exp. Ther. 299 (2001) 332-342
24. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., and James I. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92 (2001) 91-100
25. Fride E. Anandamides: tolerance and cross-tolerance to delta 9-tetrahydrocannabinol. Brain Res. 697 (1995) 83-90
26. Guindon J., LoVerme J., De Lean A., Piomelli D., and Beaulieu P. Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides?. Eur. J. Pharmacol. 550 (2006) 68-77
27. Guzman M., Lo Verme J., Fu J., Oveisi F., Blazquez C., and Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J. Biol. Chem. 279 (2004) 27849-27854
28. Ho W.S., and Randall M.D. Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br. J. Pharmacol. 150 (2007) 641-651
29. Holt S., Comelli F., Costa B., and Fowler C.J. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br. J. Pharmacol. 146 (2005) 467-476
30. Jack D.B. Bee-glue reveals anti-inflammatory properties plus. Mol. Med. Today 2 (1996) 271
31. Jarbe T.U., Swedberg M.D., and Mechoulam R. A repeated test procedure to assess onset and duration of the cue properties of (-) delta 9-THC, (-) delta 8-THC-DMH and (+) delta 8-THC. Psychopharmacology (Berlin) 75 (1981) 152-157
32. Lambert D.M., and Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?. Curr. Med. Chem. 6 (1999) 757-773
33. Lambert D.M., Vandevoorde S., Jonsson K.O., and Fowler C.J. The palmitoylethanolamide family: a new class of anti-inflammatory agents?. Curr. Med. Chem. 9 (2002) 663-674
34. Lichtman A.H., Hawkins E.G., Griffin G., and Cravatt B.F. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J. Pharmacol. Exp. Ther. 302 (2002) 73-79
35. Lichtman A.H., Shelton C.C., Advani T., and Cravatt B.F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109 (2004) 319-327
36. Lo Verme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A., and Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67 (2005) 15-19
37. Lo Verme J., Gaetani S., Fu J., Oveisi F., Burton K., and Piomelli D. Regulation of food intake by oleoylethanolamide. Cell Mol. Life Sci. 62 (2005) 708-716
38. Malan Jr. T.P., Ibrahim M.M., Vanderah T.W., Makriyannis A., and Porreca F. Inhibition of pain responses by activation of CB(2) cannabinoid receptors. Chem. Phys. Lipids 121 (2002) 191-200
39. Mazzari S., Canella R., Petrelli L., Marcolongo G., and Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300 (1996) 227-236
40. Nackley A.G., Makriyannis A., and Hohmann A.G. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119 (2003) 747-757
41. Nackley A.G., Suplita II R.L., and Hohmann A.G. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 117 (2003) 659-670
42. Pertwee R.G., Stevenson L.A., and Griffin G. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br. J. Pharmacol. 110 (1993) 1483-1490
43. Quartilho A., Mata H.P., Ibrahim M.M., Vanderah T.W., Porreca F., Makriyannis A., and Malan Jr. T.P. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99 (2003) 955-960
44. Re G., Barbero R., Miolo A., and Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet. J. 173 (2007) 21-30
45. Richardson J.D., Kilo S., and Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75 (1998) 111-119
46. Rodriguez de Fonseca F., Navarro M., Gomez R., Escuredo L., Nava F., Fu J., Murillo-Rodriguez E., Giuffrida A., LoVerme J., Gaetani S., Kathuria S., Gall C., and Piomelli D. An anorexic lipid mediator regulated by feeding. Nature 414 (2001) 209-212
47. Ross R.A., Brockie H.C., and Pertwee R.G. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur. J. Pharmacol. 401 (2000) 121-130
48. Russo R., Loverme J., La Rana G., D'Agostino G., Sasso O., Calignano A., and Piomelli D. Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur. J. Pharmacol. 566 (2007) 117-119
49. Sofia R.D., Nalepa S.D., Vassar H.B., and Knobloch L.C. Comparative anti-phlogistic activity of delta 9-tetrahydrocannabinol, hydrocortisone and aspirin in various rat paw edema models. Life Sci. 15 (1974) 251-260
50. Suardíaz, M., Estivill-Torrzús, G., Goicoechea, C., Bilbao, A., Rodríguez de Fonseca, F. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain, in press (Epub ahead of print 2007 April 19).
51. Sun Y.X., Tsuboi K., Zhao L.Y., Okamoto Y., Lambert D.M., and Ueda N. Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim. Biophys. Acta 1736 (2005) 211-220
52. Tsuboi K., Hilligsmann C., Vandevoorde S., Lambert D.M., and Ueda N. N-Cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. Biochem. J. 379 (2004) 99-106
53. Tsuboi K., Sun Y.X., Okamoto Y., Araki N., Tonai T., and Ueda N. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J. Biol. Chem. 280 (2005) 11082-11092
54. Ueda N., Yamanaka K., and Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J. Biol. Chem. 276 (2001) 35552-35557
55. Ueda N., Okamoto Y., and Tsuboi K. Endocannabinoid-related enzymes as drug targets with special reference to N-acylphosphatidylethanolamine-hydrolyzing phospholipase D. Curr. Med. Chem. 12 (2005) 1413-1422
56. Wang X., Miyares R.L., and Ahern G.P. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. J. Physiol. 564 (2005) 541-547
57. Weber A., Ni J., Ling K.H., Acheampong A., Tang-Liu D.D., Burk R., Cravatt B.F., and Woodward D. Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. J. Lipid Res. 45 (2004) 757-763
58. Welch S.P. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. Drug Alcohol Depend. 45 (1997) 39-45
59. Wiley J.L., Barrett R.L., Britt D.T., Balster R.L., and Martin B.R. Discriminative stimulus effects of delta 9-tetrahydrocannabinol and delta 9-11-tetrahydrocannabinol in rats and rhesus monkeys. Neuropharmacology 32 (1993) 359-365
60. Willoughby K.A., Moore S.F., Martin B.R., and Ellis E.F. The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther. 282 (1997) 243-247